Skip to main content
. 2017 Jun 27;2017(6):CD007047. doi: 10.1002/14651858.CD007047.pub2

Hill 2015.

Methods Phase II open‐label, randomised study
Participants People with KRAS exon 2 WT mCRC progressing on/after oxaliplatin‐containing chemotherapy
Interventions FOLFIRI plus duligotuzumab (an antibody directed against EGFR and HER3) vs FOLFIRI plus cetuximab
Outcomes Primary endpoint: efficacy. Secondary endpoints: safety and tolerability
Notes